News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Sucampo Pharmaceuticals, Inc. and Clinigen Announce Named Patient Program for European Union, Iceland and Norway to Provide Access to AMITIZA® (lubiprostone) for Chronic Idiopathic Constipation Patients


4/18/2012 10:09:58 AM

BETHESDA, Md. & BURTON-ON-TRENT, U.K.--(BUSINESS WIRE)--Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) today announced that its wholly-owned subsidiary, Sucampo AG, has implemented a Named Patient Program (NPP) to permit access to AMITIZA (lubiprostone) for patients with chronic idiopathic constipation (CIC) in the European Union (EU), Iceland and Norway. Clinigen Global Access Programs (GAP) will manage the program and will allow healthcare professionals to prescribe lubiprostone for their patients until the time that it is approved within their countries.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES